Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 17 July 2026. It includes information on: New updates Resolved Supply Issues 17-07-2026 Pharmac Weekly Update to Prescribers in Primary Care Supply issue: candesartan (Candestar) (all strengths) Issues at the supplier's manufacturing site have led to limited supply of the funded brand of candesartan tablets in New Zealand. Pharmac has worked clos

Betamethasone dipropionate (Diprosone) cr and oint Due to a manufacturing delay, the 0.05% (15g) of Diprosone cream and the 0.05% (50g) of Diprosone ointment are out of stock. Other pack sizes are available for both the ointment and cream. > Betamethasone dipropionate (Diprosone): Supply issue Oestradiol (Estradot) 100 mcg patch Stock of the 100 mcg Estradot brand of oestradiol patches (Pharmacode: 2358883) is low and may run out. The 100 mcg Estradiol TDP Mylan brand of oest

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 10 July 2026. It includes information on: New updates Resolved Supply Issues 10-07-2026 Pharmac Weekly Update to Prescribers in Primary Care Supply issue: candesartan (Candestar) (all strengths) Issues at the supplier's manufacturing site have led to limited supply of the funded brand of candesartan tablets in New Zealand. Pharmac is working clos

Insulin syringes: BD brand is moving to Embecta The BD brand of insulin syringes is being rebranded as “Embecta”. It is the same product, but the box looks different. The website has example pictures showing the change of in appearance of the boxes. > Insulin syringes: BD brand is moving to Embecta Promethazine 25 mg per ml, 2 ml ampoule All stock of this product in New Zealand (Pharmacode: 722952) is short-dated. A section 29 alternative has been listed. > Promethazine suppl

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 3 July 2026. It includes information on: New updates Resolved Supply Issues 03-07-2026 Pharmac Weekly Update to Prescribers in Primary Care Supply issue: candesartan (Candestar) (all strengths) Due to issues at the manufacturing plant, there is extremely limited supply of all strengths (4 mg, 8 mg, 16 mg, and 32 mg) of candesartan tablets (Candest

Kia ora, Pharmac has been informed by Abbott of a change in age range and label affecting PediaSure Chocolate 200 ml. The new stated age range is 3-10 years (previously 1-10years). This is due to changes in the European regulatory requirements, where the product is manufactured. There has been no change in the formulation or nutritional composition of the product. PediaSure Vanilla 200mL and PediaSure Strawberry 200mL remain suitable for ages 1-10 years and can be us

From 1 October 2026, the statin rosuvastatin will no longer require a Special Authority for funded access. This means it will be open listed and may be prescribed as a funded medicine to any New Zealander where clinically appropriate. You can read the notification on the Pharmac website here Please share this information: Please share this information with your colleagues and within your networks. If you have any questions regarding this supply issue, please contact enquiry

Kia ora, Please follow this link to our website for the June 2026 Tender Notification. Ngā mihi, Jade Matthews-Wanden | Tender Analyst

Dexamfetamine (Noumed) 5 mg tab A shipment has arrived and is available for wholesalers to order. > Dexamfetamine (Noumed) supply notice Methylphenidate Concerta: Supply of 27 mg tablets out of stock. All other strengths available. Ritalin: All strengths available Rubifen: All strengths available Sandoz XR: All strengths available Teva: Supply of 36 mg tablets low. Other strengths available. > Methylphenidate supply notice Rosuvastatin (all strengths) Stock of Rosuvastatin Vi

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 26 June 2026. It includes information on: New updates Resolved Supply Issues Supply issue: candesartan (Candestar) (all strengths) Due to issues at the manufacturing plant, there is extremely limited supply of all strengths (4 mg, 8 mg, 16 mg, and 32 mg) of candesartan tablets (Candestar brand and alternative brands). From 1 July 2026, monthly dis

We wish to inform you of several upcoming changes: Supply issues: rosuvastatin (Rosuvastatin Viatris all strengths) ursodeoxycholic acid caps 250mg (Ursosan) temozolomide 5mg capsules (Temaccord). promethazine hydrochloride injection 25 mg per ml, 2 ml ampoule (Hospira) Change to dispensing frequency and stock available: perindopril (Coversyl) all strengths progesterone (Utrogestan) 100 mg capsule Ultraproct Ointment Dexamfetamine sulfate Tab 5 mg (Noumed) Discontinuati

Kia ora Pharmac has decided to fund another brand of methylphenidate, Rubifen LA, to help ease supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD). Rubifen LA will be funded from 1 October 2026. Decision to fund a new brand of methylphenidate Thank you to everyone who provided feedback during consultation. This feedback has informed our decision. If you have any questions, please contact us at enquiry@pharmac.govt.

New medicine supply notices Benzathine benzylpenicillin (Bicillin LA) (Pharmacode: 2258072) An alternative called Benzetacil has been listed. We have asked hospitals and sexual health providers to use this alternative and prioritise Bicillin LA for people who need a lower injection volume. > Benzathine benzylpenicillin (Bicillin LA) supply notice Desmopressin acetate (Minirin) Tab 100 mcg (Pharmacode: 492620) There may be limited supply of this product until it’s resupplied i

Kia ora Supply issue: Bicillin LA injection We are writing to inform you that the supplier of Benzathine benzylpenicillin (Bicillin LA) Inj 900 mg (1.2 million units) in 2.3 ml syringe, has notified Pharmac that due to production issues arrival of the next shipment will be significantly delayed. Key Dates: The supplier has enough stock of Bicillin LA in New Zealand to supply wholesalers until late July. The next shipment is not expected until mid-November 2026. This me

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 19 June 2026. It includes information on: New updates Resolved Supply Issues Supply issue: Bicillin LA injection The supplier of Benzathine benzylpenicillin (Bicillin LA) Inj 900 mg (1.2 million units) in 2.3 ml syringe, has notified Pharmac that due to production issues arrival of the next shipment will be significantly delayed. Key Dates: The s

Kia ora, Re: Supply Issue - Efavirenz with emtricitabine and tenofovir disoproxil combination tablet. There is a long-term supply issue affecting efavirenz with emtricitabine and tenofovir disoproxil. In July 2025, Pharmac listed the TEEVIR Section 29 product as an alternative. This stock is now running low and is expected to be unavailable by late June. To maintain continuity of supply, Pharmac has listed another Section 29 alternative: Tenofovir Efavirenz Emtricitabi

Kia ora, Re: Supply Issue - rizatriptan 10 mg tablets (Rizamelt). There is a supply issue affecting rizatriptan 10 mg tablets due to an issue at the manufacturer. To ensure continuity of supply, from 12 June Pharmac has listed (funded) an alternative product: Rizatriptan Rising 10 mg orodispersible tablet. This product is not approved by Medsafe and must be prescribed and supplied in accordance with Section 29A of the Medicines Act. Further information will be added t

Kia ora Brand Change: We are writing to inform you of a tender brand change for colchicine tab 500 mcg (Colgout). Key Dates: A new brand of colchicine tab 500 mcg (Colchicine Indoco) will be funded from 1 July 2026 and awarded Principal Supply Status from 1 December 2026 to 30 June 2028. The Colgout brand will be delisted (no longer funded) on 30 November 2026. Key messages: Colchicine tab 500 mcg is currently funded and supplied in a bottle with a child resistant closu

Kia ora, Re: Supply Issue – Lansoprazole 30mg capsules We are writing to advise you of a supply issue affecting lansoprazole 30 mg capsules due to an issue at the manufacturer. To ensure continuity of supply from 1 July, Pharmac listed (funded) an alternative product: Lansoprazole 30 mg oral dispersible tablet. Please note the following important information: The alternative product is an oral dispersible tablet, not a capsule. Patients may require a new prescription.

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 12 June 2026. It includes information on: New updates Resolved Supply Issues Brand Change: colchicine tab 500 mcg (Colgout) A new brand Colchicine Indoco will be funded from 1 July 2026. The current Colgout brand will be delisted (no longer funded) on 30 November 2026 The Colgout brand is supplied in a bottle with a child resistant closure. Th